RadNet Insider Sells 15,000 Shares as Stock Falls 12% in 2026

Gregory Sorensen sold 15,000 RadNet shares (~$932,000) on March 18, 2026, reducing direct holdings by ~1.21% to 1,223,923 shares; no derivatives or indirect entities were involved. RadNet reported FY2025 revenue just over $2.0B (+11.5%) and adjusted EBITDA $20.8M (+7.4%); TTM revenue $2.04B and TTM net income of -$18.65M, with guidance implying imaging center revenue growth +18% and digital health +51% at the midpoint. Shares closed $61.99 on March 18 (1-year total return +24.85%); the insider sale is modest relative to his remaining stake and last year’s 100,000-share sale, so absent weaker fundamentals the transaction is unlikely to materially move the stock.

Analysis

The insider trimming looks more like housekeeping than a conviction sell: the CSO’s residual stake still aligns incentives with execution on a two-prong thesis (imaging volume recovery + software monetization). The market has been treating RadNet as a growth-with-profitability-risk story; the key second-order lever is software gross margins and recurring SaaS-like revenue recognition — if digital health transitions from one-off deals to subscription-like contracts, incremental margins could leapfrog current adjusted-EBITDA performance.

Competitively, large hospital systems and pure-play teleradiology/AI vendors are the two obvious pain points — hospitals can internalize volumes while AI specialists can disinter higher-margin software revenue. That produces a bifurcated outcome: downside if referral mix shifts to hospital-owned channels, upside if RadNet captures share of enterprise imaging contracts and licenses its AI stack to third parties; either path amplifies capital allocation choices (M&A vs reinvestment) and therefore multiple expansion/contraction.

Near-term catalysts to watch are quarterly imaging volume trends and the cadence of digital-health contract renewals — both variables materially affect free cash flow within 3–12 months. Tail risks include reimbursement pressure and execution slippage on software deployments; conversely, a surprise acceleration in recurring software bookings would compress time-to-profitability and justify a re-rating within 6–12 months.

Key Decisions for Investors

• Event-driven long: Allocate 1–2% NAV to a 9–12 month RDNT call spread to play conviction in digital-health ARR acceleration. Structure: buy the 12-month call ~10% out-of-the-money and sell a higher strike ~50% out to finance premium; target 2.5x upside if recurring software bookings re-rate, max loss = premium (~1–2% NAV).
• Directional equity with hedge: Buy RDNT stock (1–3% NAV) on any >10% pullback from current levels and simultaneously buy protective 6-month puts at ~20% OTM sized to limit downside to ~6% NAV. Hold through two sequential quarter prints (3–6 months) and reassess after digital-health ARR disclosure.
• Pair trade (earnings hedge): Long RDNT / Short a hospital-integrated imaging peer (equal dollar notional) for 3–9 months to isolate software execution from system-wide volume risk. Exit if the pair diverges >15% or on confirmed sequential software ARR growth.
• Macro/AI hedge: Add a modest long in NVDA (options or equity, 0.5–1% NAV) as a thematic hedge — if AI-driven imaging adoption accelerates, NVDA upside can offset multiple expansion being priced into RADNet; target 3–6 month hold to capture infra-driven re-rating.